The Annual Biosimilars Forum event series examines the actual challenges of biosimilar and nanotechnology formulated drug development for research management, leadership and support teams working in and for biosimilar drug development. The event provides a detailed overview of current development issues of follow-on biologics and guidance for their handling.
This year’s event was held in Budapest at the Event Hall of Acclesiors CRO, on 25 – 27 October, 2018 covered important issues and specific areas of debate facing clinical development teams specialized in bio- and nanosimilar development with a strong focus on statistical and regulatory perspectives. As in previous years, the program of the event was supported and complemented by leading experts from the fields of regulatory, academic and clinical research.
Based on the success of our last years’ events, we have started to prepare our next, 4th Annual Biosimilars Forum, will be held in autumn of 2019 in Budapest. The detailed programme will be available soon here, until then we recommend you read more about our previous forums!
SPEAKERS AND LECTURERS (2018 OCT):
The 3rd Annual Biosimilars Forum was hosted in Budapest in the end of October (2018), clinicians, statisticians and regulatory representatives gathered together from around the world to share with each other their perspectives on the most important issues and challenges of biosimilar research in lectures and informal discussions. Some internationally renowned expert speakers of the Forum:
President of Bawa Biotech LLC; Scientific Advisor at Teva Pharmaceutical Industries, Israel; Founding Director of American Society for Nanomedicine; USA
Professor Emeritus from the University of Toronto, Canada; Former President of Canadian Society for Pharmaceutical Scientists, Canada
Ludwig A. HOTHORN
Professor of Biostatistics at Leibniz Universität Hannover, Faculty of Natural Sciences, Hannover, Germany
Professor of Statistics, Medical and Pharmaceutical Statistics Research Unit, Department of Mathematics and Statistics, Lancaster University, UK
European Regulatory Expert; Unit Head, Austrian Medicines and Medical Devices Agency, Austria
Marina A. DOBROVOLSKAIA
Senior Principal Scientist and Head of the Immunology Section at the Nanotechnology Characterization Laboratory, USA
Lecture examples from the 3rd Annual Biosimilars Forum (2018 OCT):
• PK short course
• PK short course
• Regulatory Keynote Presentation
• Scientific Keynote Presentation
• Case Study
• Case Study
• Seminar (Nanomedicine)
SCIENTIFIC PROGRAMME COMMITTEE
Vice-Chair, Medicines for Europe, Biosimilar Medicines Group; Head of Clinical Development of Biologics, Gedeon Richter Plc.
Vice Chair, Department Clinical Pharmacology, Medical University of Vienna
Associate Professor, Section for Medical Statistics, Medical Unversity of Vienna
Statistician, Austrian Medicines and Medical Devices Agency; President, Viennese Section of IBS
Chief Scientific Officer, Accelsiors CRO Ltd.; President, Hungarian Society for Clinical Biostatistics
Director Biostatistics for Biostatistics Biosimilars, Analytics group, Novartis
Bring the Regulators and Producer Companies together into one room is an excellent idea and a beautiful concept.
–Bernd JILMA | Vice Chair, Department Clinical Pharmacology, Medical University of Vienna
I think it’s very nicely covers the whole biosimilar development process… Broader roles could benefit from this conference!
–Ildikó ARADI | Head of Clinical Development of Biologics, Gedeon Richter Plc.
These conferences are extremely useful, they provide discussions in many problems and issues. I hope very much that the series will continue …
–László ENDRÉNYI | Professor Emeritus of Pharmacology and Biostatistics, University of Toronto
The Organizers really done a very good job trying to put together such a conference where we can exchange an idea regarding the regulatory approval process and also on some actual issues in the biosimilar drug development process.
–Shein-Chung CHOW | Professor, Duke University School of Medicine
These meetings, where experts are coming together from the same or different countries bring something new: collaborations, new knowledge, so this is very precious.
–János SZEBENI | Director of the Nanomedicine Research and Education Center at Semmelweis University
We had 3 very successful and professionally fruitful events in the previous years in a row, please read more about our former forums!
LEARN MORE ABOUT THE PREVIOUS EVENTS!
At the Annual Biosimilars Forum event series, clinicians, statisticians and regulatory representatives gathered together from around the world to share with each other their perspectives on this key topic of research.
Click on the button below and take a look at the professional lectures of our events, short video interviews with the key speakers, photo galleries and more.
SOME SPEAKERS FROM OUR PREVIOUS FORUMS
Professor, Department of Biostatistics and Bioinformatics, Duke University School of Medicine, USA
Professor Emeritus of Pharmacology and Biostatistics, University of Toronto, Canada
Vice Chair, Department Clinical Pharmacology, Medical University of Vienna, Austria
Unit Head, Austrian Medicines and Medical Devices Agency, Austria
Owner at BEBAC – Consultancy Services for Bioequivalence and Bioavailability Studies, Austria
Director of the Nanomedicine Research and Education Center, Semmelweis Medical University, Budapest, Hungary